Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Actavis Closes $28B Forest Deal

By Drug Discovery Trends Editor | July 1, 2014

ActavisActavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company is now the CEO of Actavis.
The Ireland-based drugmaker said Tuesday that Brenton Saunders will serve as Actavis president and CEO. Former Actavis Chairman and CEO Paul Bisaro, who helped shepherd the company through several multibillion dollar acquisitions, will become executive chairman.
Actavis Plc had announced the cash-and-stock acquisition in February, when it was initially valued at about $25 billion. Actavis said then that Bisaro would lead the combined company.
But three months later, the drugmakers said Bisaro would move to the newly created position of executive chairman, and Saunders would take over as CEO. Actavis said the appointments reflect the complementary expertise of management teams from both companies and the increased size and complexity of the combined business.
Saunders had served as Forest Laboratories Inc. CEO for less than a year. Before that, he led optical products maker Bausch & Lomb Inc., which was acquired by Valeant Pharmaceuticals International Inc.
Actavis also added two Forest Labs board members, Dr. Nesli Basgoz and Christopher Coughlin, to its board.
Actavis shares climbed $3 to $226.07 in Tuesday morning trading, while the Standard & Poor’s 500 index rose less than 1%.
Date: July 1, 2014
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE